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Open wounds, from ulcerations or slow healing, are one of the comorbidities in diabetic patients that can lead
to amputation. Therefore, an optimal way to close and heal wounds quickly in diabetic patients is required.
Split-thickness skin grafts (STSG) offer a quick method of wound closure for diabetic patients. This article
review will look at causes of failure in STSG, and ways to optimize success.
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D
iabetes mellitus has a global impact. The Inter-
national Diabetes Federation has estimated that
globally 382 million people were affected by
diabetes mellitus in 2013, projected to increase to 592
million people by the year 2035 (1). As a result, there will
be an increase in the total number of cases of foot ulcers,
occurringinupto4%ofpatientswithdiabetesmellitus(2).
Ulcerationcontributesthegreatestcauseofnon-traumatic
minor and major amputations of the lower limb, with
diabetic foot ulcer patients having 25 times higher risk
than the rest of the population (3). The development of
diabetic foot ulcerations is multifactorial, generally due
to peripheral vascular disease, peripheral neuropathy,
and immunopathy, affecting approximately 15% of the
diabetic population at some point during their life (4, 5).
This triad of vasculopathy, neuropathy, and immunopathy
not only leads to pedal ulcerations but also increases the
susceptibility to soft tissue and osseous infections which
can ultimately lead to amputation, loss of limb, and
life. Therefore, the restoration of an intact skin barrier
is of utmost importance to prevent a portal of entry for
infection. Ideally, this is accomplished in a manner that
minimizes wound contraction to maintain function, and
minimize cosmetic disfigurement. Split-thickness skin
grafts (STSG) currently represent the most rapid, effective
method of reconstructing large skin defects (6, 7), granu-
lating tissue beds, tissue loss across joints in areas where
contraction will cause deformity, and where epithelializa-
tion alone will produce an unstable wound cover (8, 9).
For both chronic and acute wounds, STSG offer a rapid
and effective way to provide closure and healing. Ideal
conditions for successful STSG include red granulation
tissue dominating the wound bed, no visible tendon or
bone, no discernible sloughing or exudate in wound,
no residual necrotic tissue, no local signs of soft-tissue
infection, no systemic signs of infection, and no severe
peripheral arterial disease (ankle-brachial index 0.9 or
distal pulses present) (6).
Ramanujam et al. (10) showed that diabetic patients
without comorbidities had no significant difference in
healing times compared to non-diabetic patients for
STSG; however, compared to diabetic patients with
comorbidities, there was significant difference. Overall,
healing time is 1.99 weeks longer for diabetic patients than
for non-diabetic patients. Compared to patients without
diabetes mellitus, diabetic patients experience a 5.15 times
higher risk of postoperative complications after STSG.
These complications include wound dehiscence, infection,
and the need for revisional surgery. Diabetic patients
with comorbidities are at a significantly higher risk for
delayed healing from STSG compared to diabetic patients
without comorbidities and non-diabetic patients. For
diabetic patients, the presence of any preexisting comor-
bidity, history of amputation, or trauma is negatively
associatedwith the successful outcome of STSG. Further-
more, duration of diabetes, hemoglobin A1c level, chronic
kidney disease, blood urea nitrogen level, and creatinine
concentration represent modifiable characteristics that
DIABETIC
FOOT & ANKLE 
Diabetic Foot & Ankle 2014. # 2014 Ryan J. Donegan et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution-
Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and reproduction in
any medium, provided the original work is properly cited.
1
Citation: Diabetic Foot & Ankle 2014, 5: 24769 - http://dx.doi.org/10.3402/dfa.v5.24769
(page number not for citation purpose)need to be addressed when selecting patients for STSG
of diabetic foot wounds. Therefore, it is suggested that a
comprehensive medical and surgical approach is impera-
tive to maximize STSG success rate in diabetic patients
(1113).
Wound bed preparation
Successful incorporation of STSG requires vascularized
granulation tissue. Given the high prevalence of periph-
eral vascular disease in the diabetic population, it is
important to identify the need for co-management of
vascular surgeons.
Peripheral neuropathy plays a role in the etiology
of over 80% of diabetic foot lesions (14, 15), but inad-
equate perfusion always results in non-healing wounds
(16, 17). Lower extremity ischemia secondary to periph-
eral vascular disease reduces the pedal supply of oxygen,
nutrients, and soluble mediators that are involved in
the repair process (18). This lack of arterial blood flow
decreases tissue resilience, leads to rapid death of tissue,
and impedes wound healing. Clinical indications of vas-
cular disease include diminished or absent pulses, pallor
on elevation, rubor on dependency, sluggish refilling of
the toe capillaries, and thickened nails or absence of toe
hair. It is important to realize that palpable pedal pulses
do not guarantee that there is no possibility of limb-
threatening ischemia. Upon wound bed debridement and
preparation, there should be prompt signs of healing,
including the development of wound granulation within
several days; otherwise a low threshold for non-invasive
vascular studies and arteriography should be undertaken
for these patients.
Options for restoring adequate perfusion in the pre-
sence of a simple occlusion include surgical bypass to
the dorsalis pedis artery, posterior tibialis artery, and even
the more distal tarsal arteries. Endovascular techniques,
such as percutaneous transluminal angioplasty (PTA)
and cryoplasty, play an important role in patients con-
sidered poor or non-candidates for surgical revasculariza-
tion secondary to comorbidities such as coronary artery
disease, uncontrolled hypertension, diabetes mellitus, or
inadequate target vessel. For many patients, PTA can be
the sole means of treatment for peripheral artery disease.
PTA, especially in the arteries below the knee, has made
significant progress in recent years. There are some new
appliances being used in the PTA of peripheral arteries
in treating diabetic foot, such as intravascular ultrasound
ablation, cutting balloons, drug-eluting balloons, and
other special micro balloons and stents. Basco et al. (19)
reported on 126 lesions treated in 88 patients who under-
went lower extremity revascularization using cryoplasty.
Technical success rate was 97%. Limb salvage rates were
75 and 63% for patients with critical limb ischemia after
1 and 3 years, respectively. Siracuse et al. (20) reported
their results in treating 221 patients with below-knee
popliteal artery lesions. Treatment included PTA with
or without a stent, atherectomy with or without PTA/
stent, and stenting with PTA and atherectomy. Sixty-five
percent had no restenosis at 1 year, and had lower short-
term restenosis in diabetic patients compared with non-
diabetic patients. They concluded that diabetic patients
benefit most from atherectomy with PTA, and statin use
is protective against restenosis and mortality, and should
be the standard of care in peripheral endovascular in-
terventions. Wu et al. (21) performed a meta-analysis
investigating PTA versus primary stenting, to determine
which procedure is more beneficial for treating infrapo-
pliteal arterial disease. From the prospective randomized
trials included, they found 1-year outcomes did not
show any significant differences between the PTA and
the primary stenting groups, both having the same 1-year
benefit. They concluded that there was insufficient evi-
dence to support the superiority of either method. Jens
et al. (22) randomized controlled trials comparing either
balloon angioplastyor drug-eluting balloon with optional
bailout stenting, or primary stenting using a bare stent or
drug-eluting stent to one another in critical limb ischemia
patients with below-the-knee arterial lesions. Bare stent
versus balloon angioplasty and drug-eluting stent versus
balloon angioplasty trials showed low-quality evidence
ofequalefficacy.Onetrial,comparingdrug-elutingballoon
with balloon angioplasty, showed moderate-quality evi-
dence of improved wound healing and binary restenosis
in diabetic patients after 12 months; amputation and
death rate did not differ significantly. For drug-eluting
stent versus bare stent, most trials showed equal efficacy
between strategies. They concluded that balloon angio-
plasty with optional bailout stenting using bare stent
should remain the preferred strategy in treating below-
the-knee arterial lesions.
Newer alternatives to bypass include processed lipoas-
pirate cells autologous transplantation, lipo-prostaglandin
E1, granulocyte colony-stimulating factor, De Marco
formula, low-dose urokinase, and heparin-induced extra-
corporal low-density lipoprotein precipitation, which di-
rectly removes fibrinogen levels from the cardiovascular
system and improves microvascular circulation (23).
Bioengineered alternative tissues
Pedal wounds with exposed bone, ligament, and tendon
pose additional challenges as direct placement of STSG
havehighratesoffailureasthesestructuresdonotprovide
adequate vascular wound bed to allow take and nourish-
ment of skin graft. The other complication of STSG over
these structures is adhesions, limiting function and result-
ing in breakdown. Tendon-exposed wounds should be
closed quickly to prevent tendon desiccation and resultant
functional disability, but granulation tissue over tendon
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over such structures requires additional wound bed
preparation. Successful options include bioengineered
alternativetissues(BAT),allografts,andnegative-pressure
wound therapy (NPWT). Since chronic ulcers often lack
healthy, vascularized tissue to support artificial dermis,
recipient bed preparation for dermis implantation via
NPWTor allografting may be necessary. NPWT promotes
granulation growth, while allografting stimulates angio-
genesis. In a series of 20 patients, Egemen et al. (25)
applied NPWT to the wound bed prior to grafting. The
vacuum was set to a continuous negative pressure of
125 mm Hg, with dressings changed on alternate days.
Adequate granulation tissue formation was achieved,
allowing for direct application of meshed STSG.
BAT are products derived from human, animal, and
synthetic tissues that have been manufactured, cleaned,
or otherwise altered. BAT can be categorized as dermoin-
ductive or dermoconductive. Dermoinductive products
contain viable cells, including fibroblasts and keratino-
cytes, which are delivered to the non-healing wound site
with the goal of activating senescent cells in the chronic
diabetic wound by releasing cytokines and growth factors
that are produced in the grafted cells. Dermoinductive
products should be reserved for more superficial wounds.
This includes products such as Apligraf (Organogenesis,
Canton, MA) and Dermagraft (Advanced Biohealing,
San Diego, CA), which have both demonstrated clinical
efficacy (26, 27). In contrast, dermoconductive products
provide an organized scaffold to facilitate cell migration
of fibroblasts and serve as a template for the formation of
neodermis, which is histologically similar in appearance
and structure to normal dermis. This provides a durable
dermal layer necessary for granulation tissue formation,
allowing a skin graft to be placed over the neodermis for
definitive wound closure. Examples of this type of tissue
include Integra Bilayered tissue (Integra LifeSciences,
Plainsboro, NJ) and hMatrix (Bacterin, Belgrade, MT).
Thorough debridement must be performed before appli-
cation of dermoconductive products to remove biofilm
and necrotic tissue. This category of products should
be reserved for deeper wounds with exposed fascia,
tendon, or bone (28). The failure rate of skin grafting
on neodermis is 7%, which is lower than that of direct
skin grafting on tendons with or without granulation
tissue (29). As the neodermis matures, it appears golden
yellow, which indicates its readiness for skin grafting,
usually occurring between 16 and 28 days after artificial
dermis placement. Shoreset al. (30) placed Integra Bilayer
Matrix Wound Dressing directly over exposed tendons
with a subsequent STSG several weeks later in 42 patients.
STSG was applied after generation of highly vascularized
neodermis, on average 35.3 days afterthe initial placement
of Integra. The size of the tissue defect including the
area of tendon exposure ranged from 4 cm
2 to 336 cm
2
with an average of 65.1 cm
2. Average STSG thickness
was 0.011 inches. There was 92.5% take in all skin grafts,
with all patients exhibiting durable skin coverage at the
end of their follow-up period. With physical and occupa-
tional therapy, patients were able to attain an average
range of motion in their skin grafted joints of the lower
extremity that was 90.6% compared to their contralateral
side. Yeong et al. (24) reported on 23 patients with 33
wounds, in which artificial dermis was used to prepare
tendon-exposed wounds for STSG, 11 of which were
chronic ulcers. Thirty-nine percent of the patients had
underlying diabetes mellitus, and 55% of the wounds were
found in the lower extremities. The mean area of artificial
dermis implantation was 67 cm
2, with mean duration
from artificial dermis implantation to STSG 21 days.
Overall success rate was 82%, with 63% in the chronic
ulcer group. Silverstein (31) also described the use of
this technique to close tissue defects of five diabetic feet.
All (100%) wounds healed with complete coverage of
exposed bone, tendon, cartilage, and fascia.
Some clinicians have also suggested the use of NPWT
on meshed Integra to speed rates and success of revascu-
larization. Much like STSG, hematoma and shearing
forces can interrupt healing and lead to loss of artifi-
cial dermis. Helgeson et al. (32) immobilized Integra for
5 days. As soon as the implanted artificial dermis changed
to a golden yellow color indicating formation of the
neodermis, the outer silicone layer was removed and
STSG were applied. Helgeson harvested skin grafts at
least 0.008 inches thick for grafting on the neodermis.
When exposed tendon or bone is not present in the
wound bed, and adequate vascular supply is present, an
algorithmic approach to wound healing can be applied
to maximize STSG success, focusing on local wound
conditions and their management.
Tissue management
Necrotic tissues in a wound should be removed as it
prevents proper assessment of the wound bed, and also
can be a source of bacterial growth. Of note, bacterial
colonies can produce unwanted metalloproteinases that
negatively affect extracellular matrix (ECM) components
during the healing process, and form biofilm in wound
beds. Biofilm is bacterial colonization of the wound
surface that is highly resistant to antibiotic treatment,
including standard treatments such as systemic antibiotics
(3337). This resistance is partially due to the low meta-
bolic rate of these colonies, which directly impacts the
mechanism of action of commonly used oral or parenteral
antibiotics as well as the polymicrobial nature of the
biofilm (3842). In addition, these colonies attach to
the surface of wounds and surround themselves in a
relatively protected microenvironment consisting of an
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increased resistance to antimicrobial, immunological, pre-
datory, and chemical attack (4850). Once established,
biofilms are highly resistant to removal and eradication
(51). The reason acute wounds progress through stages
of healing, while chronic wounds appear to stall in the
inflammatory stage, is likely because of persistent colo-
nization by bacteria (52), leading to persistent inflamma-
tory responses with abnormal cytokine and matrix
metalloproteinase levels (53, 54) (Fig. 1).
James et al. (55) reported the presence of biofilms in
60%ofchronicwounds,definedasopenfor30days,versus
6% of acute wounds (55). Unlike an infection, mature
biofilm develops within 10 hours and persists indefinitely
while thewound remainsopen (56). Once maturedbeyond
this (48 hours), biofilm becomes increasingly resistant
to antibiotics (51). Six features have been used to indi-
cate the presence of bacterial biofilm in human chronic
wounds (57). These include indicators such as a pale
wound bed, friable granulation tissue, a yellow discharge,
necrotic tissue, a clear slime, and aputrid smell. At present,
unless the wound is heavily populated, tissue biopsies or
swabs are required combined with microscopic identifi-
cation techniques to confirm the presence of a wound
biofilm. Scanning electron microscopy (SEM) has also
been used to show the presence of biofilms within wound
tissue (33). In diabetic foot ulcers, diagnosis is generally
based on clinical signs and symptoms of inflammation.
Clinically seen will be wound bed color change, friable
granulationtissue,abnormalodor,increasedserousexudate,
and pain at wound site with infection.
Inflammation and infection control
Studies have shown that many commercial topical agents
and wound dressings are ineffective against biofilm
infections (58). Instead, thorough debridement and sys-
temic antibiotics, where antibiotic treatment is tailored
specifically to each wound infection, together with a
rotating topical antiseptic for the extremely recalcitrant
wounds is required (59).
Virtually all chronic diabetic wounds contain bacteria,
ranging from contamination, colonization, and critical
colonization to infection (60). Usually critical coloniza-
tion and infection stages impede wound healing. The
impact of bacteria in a wound depends on three factors:
bacterial load, bacterial strain virulence, and capability
of host to mount resistance. In diabetic patients, the effect
of bacterial loads can be observed even at a lower count
or even with the normal skin flora due to a weak im-
mune system and impaired leukocyte function. Infections
in diabetic foot ulcers are commonly polymicrobial
and contain both aerobic and anaerobic bacteria (61).
The most common bacteria observed in chronic wound
infections are Staphylococcus aureus (93.5% of ulcers),
Enterococcus faecalis (71.7%), Pseudomonas aerugi-
nosa (52.2%), Coagulase-negative Staphylococci (45.7%),
Acinetobacter baumannii (13%), and Klebsiela pneumonia
(6.5%) (55, 62). Many studies have reported the evidence
of antibiotic-resistant isolates in biofilms, in particular
methicillin-resistant Staphylococcus aureus (MRSA),
vancomycin-resistant Enterococcus (VRE), and multi-
drug-resistant Acinetobacter baumannii (63, 64).
Preoperative wound swabs are routinely performed
to identify subclinical wound bed colonization, as well
as specific strains of bacteria, such as Pseudomonas
aeruginosa or Staphylococcus aureus, which can have
detrimental effects on graft take (65, 66). However,
it remains important to know whether a near-sterile
recipient is required for successful skin grafting, as not
allwoundscanbeclearedfrombacteria,despiteprolonged
antibiotic administration and sustained wound bed pre-
paration (67). In an analysis by Bosman et al. (6), wound
swabs taken immediately before grafting showed that
approximately half the wound beds (53%) had been
contaminated, the other half (47%) being sterile. MRSA
was detected in five cases, and either Pseudomonas
aeruginosa or Staphylococcus aureus was detected in
23% of thewounds. Contaminatedwounds did not display
a lower mean graft take percentage than near-sterile
wounds (87% vs. 90%, respectively). Wounds containing
either Pseudomonas aeruginosa or Staphylococcus aureus
did have inferior outcome (mean take percentage 78.9%
vs. 91.3%, respectively) whereas diabetes also appeared
to be a deteriorating factor (mean take percentage
83.0% vs. 90.7%) (9, 53, 6874). They found that although
wound cultures showed that positive swab cultures did not
impede good graft take, the presence of specific strains,
suchasPseudomonasaeruginosaorStaphylococcusaureus,
infers suboptimal outcome. They concluded that qualita-
tive instead of quantitative analysis of the wound swab,
whereby specific strains of bacteria are identified, is
recommended. Wolcott and Rhoads (53) observed that
the chronic wounds treated by specifically targeting Fig. 1. Bioﬁlm present on wound bed.
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wounds. When combined with antibiofilm compounds,
the use of antibiotics declined 25% during the 4-year
study period.
Chronic wounds often exhibit a highly persistent
inflammatory phenotype, epitomized by the influx of
polymorphonuclear leukocytes (PMNLs) to the wound
site, elevated matrix metalloproteinases (MMPs), and
an imbalance of several cytokines (69). The continued
presence of bacteria in the wound further exacerbates
thesituationbycausingadditionalinfiltrationbyPMNLs,
together with MMP production (51). Diabetic patients
exhibit further dysregulated inflammatory and immune
responses that predispose them to chronic wound infec-
tions. In diabetic chronic wounds, there is a disruption
of the balance between ECM synthesis and degradation
(70). MMPs regulate extracellular structural proteins
and consequent tissue remodeling (71). Biopsies carried
out on non-healing ulcers have shown higher presence of
MMPs than those carried out on healing wounds. This
altered MMP expression in chronic ulcers result in exces-
sive matrix degradation, preventing normal matrix for-
mation and remodeling, leading to formation of chronic
wounds (72). The inflammatory stage is extended in the
non-healing wounds and this is reflected by the continued
presence of neutrophils and elevated MMP. Amato et al.
(70) showed that levels of the collagenases, MMP-1 and
MMP-8,areoverexpressedinhumannon-healingwounds
compared to normal healing wounds, and the role of
MMP-8 appears to be predominant because of a higher
over-expression. This chronic inflammatory condition
results in the continual infiltration by poly and mono-
nuclear cells that include neutrophils, PMNLs, macro-
phages, and foreign body giant cells at the site of injury
resulting in a continuous secretion of potent proteases,
such as collagenases, gelatinases, and neutrophil elastase
into the wound. Nguyen et al. (75) has also shown that
diabetic biofilm-containing wounds had significantly less
TLR 2, TLR 4, interleukin-1b, and tumor necrosis factor-
aexpressionthanwild-typewoundswithbiofilm.Whereas
both groups had similar bacterial burden and neutrophil
infiltration after development of biofilms at 3 days post-
wounding, diabetic wounds, however, had significantly
less neutrophil oxidative burst activity.
The upregulation of proteolytic enzymes, especially
MMPs, causes excessive matrix degradation (7680).
The MMPtissue inhibitor of metalloproteinase (TIMP)
balance is critical for regulating cell-matrix composition.
Many studies have documented the important role of
this balance in the pathophysiology of chronic wounds
(74, 81). Hyperbaric oxygen therapy (HBOT) has been
shown to significantly decrease MMP protein levels in is-
chemic wound tissue, while the level of TIMP significantly
increases (73).
Wound bed debridement
There is debate over the depth of tissue debridement
necessary to remove biofilm, and even after debridement,
repopulation of biofilm within 24 hours can occur (82).
Therefore, maintenance debridement in a clinic setting
may be required to decrease the biofilm load after the
initial operative debridement.
Debridement helps to reduce the bacterial burden
within the wound, controls ongoing inflammation and
malodor, and encourages formation of granulation tissue
(60). The molecular and cellular environment of chronic
wounds should be converted to resemble that of acute
wounds to allow rapid healing, and for this to occur, non-
healing wounds may require repeated debridement (83).
There are multiple techniques that can be used for the
debridement of necrotic, sloughy, fibrous, and unhealthy
tissue. The options for debridement include surgical and
mechanical methods. A wound bed may also be prepared
by variousnon-surgical debridement techniques: autolytic
debridement facilitated by interactive dressings, larval
therapy using sterile maggots, and enzymatic debridement
with ointments containing papain, urea, or collagenase
mixtures. Autolytic debridement can be slow and can take
a long time to be effective (84). Enzymatic debridement
finds usewhenother techniques arenotfeasibleduringthe
initial management of a chronic wound (85). Mechanical
(wet-to-dry) debridement damages healthy granulation
tissue (86). NPWT can also be a useful adjunct to bio-
film reduction. Morykwas et al. (87, 88) and Timmers
et al. (89) suggest that negative pressure therapy expe-
dites wound healing through the evacuation of drainage,
promotion of angiogenesis, granulation tissue formation,
and biofilm reduction. Gabriel et al. (90) demonstrated
fewer days of treatment, more rapid wound closure, and
fewer hospital days with the use of negative pressure
therapyandantimicrobialsolutiontosoakthewoundbed.
Topical therapy
Antimicrobial treatment guided by superficial wound
culture has been challenged repeatedly in the literature
(9194). Slater et al. (41) reported that only 62% of
microorganisms identified through swab cultures corre-
lated with deep tissue cultures, and different microorgan-
isms were found in the swab cultures as compared with
the deep cultures. Also relevant, superficial wound culture
might not accurately reflect the diversity of the bacteria
present in the chronic wound enveloped by biofilm. The
use of polymerase chain reaction microbial speciation
and quantification is increasingly recognized as a more
efficient and accurate method of guiding topical biofilm
treatment in the chronic diabetic wound (9598).
There is a growing consensus that systemic antibiotics
may be ineffectual in the treatment of biofilm and/or
mild infections associated with chronic diabetic wounds,
and can aid in the development of antibiotic resistance
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and gels) have long been used for the prevention and
treatment of localized, mild to moderate, soft-tissue wound
infection. Triple antibiotic, gentamicin, iodine-based, and
silver-based are some examples of commonly used topical
antimicrobials.
Silver-impregnated dressing materials are commonly
used because of its purported antimicrobial properties
identified through in vitro studies (98, 102105). Beele
et al. (106) reported in a small prospective randomized
trial that the use of a silver-impregnated dressing de-
creases the likelihood of conversion from colonized
wound to a clinically infected wound as compared with
a non-silver-impregnated dressing. In one study, it was
observed that 90% of all sessile bacteria within the bio-
film progressively died within 24 hours in the presence
of silver-containing wound dressings (107). Thorn et al.
(108) investigated the antimicrobial effectiveness of silver-
and iodine-containing wound dressings on preformed
biofilms of Pseudomonas aeruginosa and Staphylococcus
aureus grown in biofilm model. It was found that the
iodine dressing was more efficacious than the silver
dressing on biofilms. In a recent retrospective single-
center study, Wolcott and Rhoads (109) evaluated the
frequency of complete healing in subjects with a chronic
wound in a limb with critical limb ischemia when
managed using biofilm-based wound care. In total, 77%
of the wounds healed completely and 23% were classified
as non-healing.
Biologic debridement
Over the past decade, biologic debridement using mag-
gots has become increasingly popular. The maggots are
highly selective and rapid, but often need to be combined
with other forms of debridement after initial larval
application (110, 111). The larvae of the green butterfly
Lucilia sericata (112) or Lucilia cuprina (113) can be used
for biological debridement to digest the necrotic tissue,
and they also secrete bactericidal enzymes. This approach
is effective in wounds with MRSA and beta hemolytic
Streptococcus.
Surgical debridement
Surgical debridement, the current gold standard against
which other forms of therapy are measured, is quick and
effective, although expensive as it requires an operating
room and many hospital admissions (86). Surgical debri-
dement is the fastest means of debridement, allowing
surgeons to accurately assess the severity and extent of the
wound. A drawback of sharp surgical debridement is the
non-selective nature of the method, which endangers
normal healthy tissues with the risk of accidental removal
(114). In the presence of ischemic ulcers, it is critical that
management should aim toward restoring tissue perfusion
prior to aggressive wound debridement or aggressive
surgery to ensure wound healing.
Hydrosurgery combines both physical and surgical
debridement techniques allowing for precise, controlled,
and expedited debridement (115). Hydrosurgery allows
for select removal of necrotic tissue, while decreasing
debridement times by 39% (60). Caputo et al. (116)
published a random controlled trial comparing hydro-
surgerydebridementtoconventionalsurgicaldebridement
in patients with diabetic and venous leg ulcers (35).
On average, hydrosurgery debridement was quicker by
about 7 minutes per procedure, and required significantly
less instruments and sterile saline. The median time for
wound closure was similar in both groups. Mosti et al.
(115) compared use of hydrosurgery debridement to moist
dressings in patients with vascular leg ulcers. The mean
time to debride the wound was 58 minutes, and the
average time to obtain a clean wound was reduced by
nearly 5 days compared to wet-to-dry dressings. Hydro-
surgery also minimizes the amount of normal tissue that
is accidentally removed by surgery, and in most cases the
wound bed is ready for immediate skin grafting (117).
Vanwijck et al. (117) reported on 167 wounds treated
by hydrosurgery. Of all the debrided wounds, 95% were
immediately covered with an autologous split-thickness
meshed graft. Hydrosurgery left a smooth wound surface,
which allowed immediate skin grafting in the majority of
patients. For all but 8 patients, the engraftment was total.
Studies have demonstrated that hydrosurgery efficiently
reduces the bacterial load of the wound and prevents
the diffusion of microbial contamination deeper into the
wound (118) (Fig. 2).
Ultrasound therapy
The use of acoustic energycontinues togrow in popularity
as a method of biofilm debridement. There are mainly
two classified effects of ultrasound on tissue: thermal and
Fig. 2. Surgical wound bed free of bioﬁlm after hydrosurgery
debridement, ready for split-thickness skin grafting.
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rides necrotic tissue as a result of cavitation (120). Low-
intensity ultrasound is thought to promote wound healing
predominantly by acoustic streaming effects such as
increased protein synthesis and production of growth
factors (121). In addition, low-frequency ultrasound
has been reported to have antibacterial effects (122, 123),
and enhance fibrinolysis in vitro (124, 125). Ennis et al.
(126) compared low-frequency (40 kHz) non-contact
ultrasound to placebo in 55 diabetic patients with recalci-
trant foot ulcers in a randomized, multicenter, double-
blinded study. At 12 weeks, they reported significantly
higher healing rates in the treatment group. Kavros
et al. (127) published another study on 163 patients
with chronic lower extremity wounds. In the retrospective
study, they reported significantly higher percentage of
wounds healed with low-intensity and low-frequency
ultrasound compared to standard care alone. A recent
meta-analysis reported significantly improved complete
healing rates with low-frequency and high-intensity ultra-
sound (2030 kHz, 5060W/cm
2) compared to sharp
debridement at 3 and 5 months (9).
Hyperbaric oxygen therapy
Reported benefits of HBOT are its detrimental effect on
bacteriavia the production of oxygen free radicals and by
enhancing leukocyte activity (128). The reports of anti-
microbial effects target anaerobic bacteria by increasing
oxygen concentrations in deeper tissues. Chen et al. (129)
reported increased limb salvage rates (78.3%) among
patients with infected diabetic wounds who underwent
greater than 10 HBOT treatments. Although literature
on evaluating the effect of HBOT on biofilm reduction
or eradication is rare.
STSG management
After harvesting of STSG, to ensure success, seroma/
hematoma must be managed, along with prevention of
shear forces that would disrupt the plasmotic phase
and angiogenesis phase while the STSG is being incorpo-
rated on to the wound bed. To achieve all of the above
requirements, a uniform pressure over the entire grafted
area through a non-adherent, semi-occlusive, absorbent
dressing material is required. NPWT finds a role both
before split-thickness skin grafting bydecreasing bacterial
load and assisting with wound bed preparation, as well
as aftergrafting by fixating graft and reducing/eliminating
seroma/hematoma (130). Graft take and complication
rates have significantly improved because of the prefer-
ential use of meshed grafts and the introduction of NPWT
(7, 131, 132) (Fig. 3).
Blume et al. (133) compared conventional therapy (CT)
dressing, cotton bolster/sterile compressive/stainless steel
gauze dressing that is used for at least 5 days, to NPWT
using reticulated open cell foam (NPWT/ROCF). One
hundred and forty-two patients underwent STSG place-
ment, 79 wounds being diabetic foot ulcers. Grafting area
was similar between NPWT/ROCF (45.4 cm
2) and CT
(47.4 cm
2). Mean graft take at the first follow-up was
95% for NPWT/ROCF compared to 86% for CT, with
maximum graft take of 96% for NPWT/ROCF compared
to 83% for CT. There were significantly fewer repeated
STSGs required in the NPWT/ROCF group (3.5%) com-
pared to the CT group (16%). There were fewer complica-
tions (seroma/hematoma/infection) to graft failure in
the NPWT/ROCF group compared to the CT group.
The ROCF dressing conformed to the wound geometry
with negative pressure, promoting skin graft adherence
while removing exudates and edema from the surround-
ing tissues. Egemen et al. (25) used standard black
polyurethane foam with a continuous negative pressure
of 75 mm Hg for both wound bed preparation and
management post-application STSG. The mean number
of silver-impregnated foam dressing for wound bed
preparation was 2.9, with a mean of 2.6 NPWT foam
changes after skin grafting. All wounds completely healed
without the need for further debridement or re-grafting.
(Fig. 4).
There are limitations and shortcomings to this review
article. One limitation is that this is not a meta-analysis;
not every study included was a rigorous scientific endea-
vor, and not every study investigating STSG was included.
Conclusion
Graft survival is predicated on several factors: histori-
cally, graft failure rates were high and primarily attrib-
uted to infection (7), highlighting the importance of
biofilm management and eradication; as well preventing
shearing, seroma, and hematoma formation beneath the
graft with immobilization to allow for the initial take
or incorporation, which occurs by diffusion of nutrition
Fig. 3. Negative pressure wound therapy with foam holding
split-thickness skin graft in place, preventing seroma, hematoma,
and shear forces.
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STSGs must be placed on a well-vascularized bed with
low bacterial counts to prevent infection. Revasculariza-
tion generally occurs between days 3 and 5 by reconnec-
tion of blood vessels in the graft to recipient site vessels
or by ingrowth of vessels from the recipient site into the
graft (134). Skin grafts generally will not take on poorly
vascularized wound beds, such as bare tendons, cortical
bone without periosteum, heavily irradiated areas, or
infected wounds. However, virtually any tissue type with
a vascular granulating bed is acceptable for grafting
(135). NPWT has been shown to provide many aspects
of STSG success by promoting granulation tissue, low-
ering bacterial counts, and removing accumulated fluid,
such as hematoma/seroma, both of which reduce the
chronic inflammatory process that occurs in chronic
wounds such as elevated MMPs.
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